Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,663 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Safety and Tolerability in Healthy Subjects Clear all

Conditions: Healthy Volunteers
Interventions: TAK-105-a, TAK-105-a Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Tempe, Arizona • Las Vegas, Nevada • Austin, Texas

Conditions: Healthy Volunteers
Interventions: LY3050258, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Rheumatoid Arthritis
Interventions: AC430; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Drug Toxicity
Interventions: Placebo, MW151, 10mg, MW151, 20mg, MW151, 40mg, MW151, 80mg, MW151, 160mg; Drug
Lead sponsor: Linda Van Eldik; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Substance Use Disorders (SUD)
Interventions: CVL-936, Matching Placebo; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Healthy
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stroke, Ischemic, Pain, Postoperative, Substance Abuse, Subarachnoid Hemorrhage
Interventions: Placebo, NP10679; Drug
Lead sponsor: Neurop Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis (RA)
Interventions: LY4213663, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Anniston, Alabama • Phoenix, Arizona • Clearwater, Florida + 6 more

Conditions: Healthy
Interventions: LY3074828, Pre-filled syringe (PFS), Autoinjector (AI); Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Influenza
Interventions: AVI-7100 versus placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer
Interventions: Placebo RO4602522, RO4602522, moxifloxacin, moxifloxacin placebo; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Nasolabial Folds, Lipoatrophy, Lipodystrophy
Interventions: TAT4 Gel concentration A, TAT4 Gel concentration B, Placebo; Drug
Lead sponsor: Topokine Therapeutics, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteer, Renal Impairment
Interventions: PF-06700841; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Healthy Volunteer
Interventions: ABBV-859, Placebo for ABBV-859; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Spinal Muscular Atrophy
Interventions: Risdiplam, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Daratumumab, Placebo, rHuPH20; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Participants
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Infections, Bacterial
Interventions: GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Painful Diabetic Neuropathy
Interventions: Oral dose CNTX-6016 or oral dose Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatic Impairment, Moderate Impaired Hepatic Function
Interventions: Quizartinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy Volunteers
Interventions: MRT-6160, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: CC-92480, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Study of TAK-105 in Healthy Adults

A Study of LY3050258 in Healthy Participants

Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

MW151-101: First-in-human Study of MW151

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

A Study of Tirzepatide (LY3298176) in Healthy Participants

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

A Study of Injections of LY3074828 in Healthy Participants

Testing the AVI-7100 Flu Drug in Healthy Volunteers

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers

Renal Impairment Study of PF-06700841

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

First-in-human Study of MRT-6160 in Healthy Subjects

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects